Delivery Order SPE2DB24D3013-SPE2DB25FFKFW

Award Date 3/20/25
Potential Completion Date 3/21/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,921.80 fixed-price delivery order is for the supply of 4567222338 units of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a specialty pharmaceutical product. The contract has a performance period through February 11, 2025 and was awarded on February 10, 2025. This delivery order is part of a larger $999,999,999...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,173.75, is a Delivery Order for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The contract has an ultimate completion date of December 23, 2024 and is a Firm Fixed Price contract. The contract was not designated with a set-aside. AmerisourceBergen Drug Corp...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $63,817.20 firm fixed-price delivery order is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The contract has an ultimate completion date of June 12, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $6,842.07, is for the delivery of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This federal contract award is a delivery order valued at $1,069.48, awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medication. It has an ultimate completion date of October 9, 2024 and is a firm fixed-price contract. AmerisourceBergen holds several large Indefinite Delivery Contracts (IDCs) with the DLA and other federal agencies, valued up to...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the provision of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The award is valued at $5,355.95 and has a period of performance through June 24, 2024. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $13,204.36 for the delivery of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a medical product. The contract has an ultimate completion date of July 16, 2024 and is designated as a Firm Fixed Price contract. It is not associated with any set-aside requirements. Amerisourcebergen Drug Corp...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,570.20 firm fixed-price delivery order is for the BYDUREON BCISE 2 MG AUTOINJECT 0.85ML product, with a completion date of May 31, 2024. This award is a part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,083.40 firm fixed price delivery order is for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML medical devices. The contract has an ultimate completion date of December 28, 2023 and was awarded on December 27, 2023. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) that...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,298.62, is for the delivery of 4566847901 BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The contract has an ultimate completion date of January 7, 2025 and is a Firm Fixed Price Delivery Order. The contract was not set aside for any specific business type. AmerisourceBergen Drug...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB25FFKFW
    Delivery Order

This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $1,662.45, is a Firm Fixed Price Delivery Order for the supply of BYDUREON BCISE 2 MG AUTOINJECT 0.85ML, a pharmaceutical product. The contract has an ultimate completion date of March 21, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/19/25, 9:53 AM